Lilly Strong - Search News

Weight Loss Drug Demand Drives Eli Lilly Sales

Lilly reassures investors that weight-loss drug demand is strong, shares rise

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs. Lilly said o

The Motley Fool · 19d

Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels. Eli Lilly now expects revenue to be approximately $13.

Business Insider · 12h

LLY Earnings: Weight Loss Drug Demand Drives Eli Lilly Sales as Investors Eye Next-Gen Treatments

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in

12h

Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

Business Insider23d

Eli Lilly & Co: Strong Long-Term Growth Prospects Amid Q4 Revenue Shortfall Justify Buy Rating

However, the strong revenue guidance for 2025 has eased investor concerns, indicating that the company remains on a solid growth trajectory. Anderson believes that Eli Lilly is well-positioned to ...

12hon MSN

Bernstein reiterates Eli Lilly stock Outperform with $1,100 target

Bernstein research firm maintained a positive outlook on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Weight Loss Drug Demand Drives Eli Lilly Sales

Trending now